Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1431 studies found for:    VEGF
Show Display Options
Rank Status Study
1 Recruiting Prospective Randomized Trial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD)
Condition: Exudative Age-related Macular Degeneration
Interventions: Drug: 24GyE proton and Anti-VEGF;   Drug: 16GyE and anti-VEGF;   Drug: Sham Irradiation and anti-VEGF
2 Completed
Has Results
Omega-3 Supplementation and Vitreal VEGF Levels in Wet-AMD
Condition: Exudative Age-related Macular Degeneration.
Interventions: Dietary Supplement: Anti-VEGF plus AREDS-2;   Dietary Supplement: Anti-VEGF plus AREDS-1
3 Completed Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema
Condition: Diabetic Macular Edema
Intervention: Drug: VEGF Trap-Eye
4 Recruiting Maternal Serum Vascular Endothelial Growth Factor in Pregnant Women With Foetal Growth Restriction
Condition: Foetal Growth Restriction
Interventions: Device: obstetric Ultrasound;   Other: serum Vascular Endothelial Growth Factor
5 Completed
Has Results
Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)
Condition: Macular Degeneration
Intervention: Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
6 Active, not recruiting VEGF Signaling Promotes Cell Growth and Metastasis in Extrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway (ECC)
Condition: Extrahepatic Cholangiocarcinoma
Intervention: Procedure: surgical treatment
7 Recruiting UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-VEGF Effects in Patients With neovascuLar AMD
Condition: Neovacular Age-related Macular Degeneration
Intervention: Procedure: VEGF level assessment
8 Unknown  Anterior and Posterior Segment Vascular Changes Following Laser and Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Diabetic Retinopathy
Condition: Diabetic Macular Edema
Intervention:
9 Active, not recruiting Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement
Condition: Macular Edema
Interventions: Biological: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321);   Procedure: Laser photocoagulation
10 Completed
Has Results
Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer
Condition: Rectal Cancer
Interventions: Drug: Avastin (Bevacizumab, RHUMAB VEGF);   Drug: Capecitabine;   Radiation: Radiation Therapy
11 Withdrawn A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Conditions: Carcinoma, Renal Cell;   Glioblastoma;   Carcinoma, Hepatocellular
Interventions: Drug: Crizotinib plus VEGF inhibitor combinations;   Drug: Crizotinib plus axitinib;   Drug: Crizotinib plus sunitinib;   Drug: Crizotinib plus bevacizumab;   Drug: Crizotinib plus sorafenib
12 Withdrawn Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients
Conditions: Glioma;   Meningioma
Intervention: Procedure: Blood test
13 Completed
Has Results
VEGF Trap in Treating Patients With Metastatic Breast Cancer
Conditions: Metastatic Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Intervention: Biological: ziv-aflibercept
14 Withdrawn Does Vascular Endothelial Growth Factor (VEGF) or Complement Factor H Gene Polymorphism Play a Role in the Treatment Success With VEGF Inhibitors in Patients With Choroidal NeoVascularization (CNV)?
Conditions: Choroidal NeoVascularization;   Age-Related Macular Degeneration
Intervention: Genetic: VEGF genotyping
15 Completed VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer
Interventions: Drug: docetaxel;   Biological: ziv-aflibercept;   Other: laboratory biomarker analysis;   Other: pharmacological study
16 Completed Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema)
Condition: Macular Edema
Intervention: Biological: VEGF Trap-Eye (BAY86-5321)
17 Completed Differential Regulation of VEGF, Cadherin, Angiopietin 2 by Trigger Oocyte Maturation With GnRHa vs hCG in Donors
Condition: Messurement Levels of VEGF
Intervention:
18 Completed Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD
Condition: Macular Degeneration
Intervention: Drug: VEGF Trap
19 Unknown  Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy
Condition: Wet AMD
Intervention:
20 Completed Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD
Condition: Neovascular Age Related Macular Degeneration
Interventions: Drug: VEGF Trap;   Biological: VEGF Trap

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years